RODIN THERAPEUTICS, INC.
Small molecule HDAC6-selective inhibitors for Alzheimer's disease treatment
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2013
- Latest Form D
- $10.8M, Sep 2017
- Total capital
- $11M
- Federal grants
- $217K
- 1 award · 2015
- Rank in peer group#348 of 392
- Private capital raised
- $10.8M
- 1 Form D · last Sep 2017
- 109 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 14 pending · first 2018
- Rank in peer group#20 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$10.8M
- Federal grantHealth and Human S · Phase I · HDAC2 Inhibitors for the Treatment of Cognitive Deficits in Alzheimer's Disease$217K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
27months
from RODIN THERAPEUTICS, INC.’s first federal award to its first private round.
- First federal award · Jun 2015
- Health and Human S · $217K
- First Form D · Sep 2017
- $10.8M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#20 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Adam RosenbergExecutive Officer, DirectorNamed in SEC Form D filings
- Bruce BoothDirectorNamed in SEC Form D filings
- Kees BeenDirectorNamed in SEC Form D filings
- Samantha SingerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 20- GrantedBicyclic Inhibitors Of Histone DeacetylaseUSPTOUS 10,793,567
- GrantedBicyclic Inhibitors Of Histone DeacetylaseUSPTOUS 10,696,673
- GrantedBicyclic Inhibitors Of Histone DeacetylaseUSPTOUS 10,519,149
Show all 20 patent records
- Bicyclic Inhibitors Of Histone DeacetylaseOct 6, 2020 · US 10,793,567Granted
- Bicyclic Inhibitors Of Histone DeacetylaseJun 30, 2020 · US 10,696,673Granted
- Bicyclic Inhibitors Of Histone DeacetylaseDec 31, 2019 · US 10,519,149Granted
- Heterobicyclic N-aminophenyl-amides As Inhibitors Of Histone DeacetylaseSep 24, 2019 · US 10,421,756Granted
- Hetero-halo Inhibitors Of Histone DeacetylaseJul 12, 2018 · Application 15741657Pending
- Inhibitors Of Histone DeacetylaseMay 29, 2018 · US 9,981,920Granted
- Bicyclic Inhibitors Of Histone DeacetylaseApr 24, 2018 · US 9,951,069Granted
- Bicyclic Inhibitors Of Histone DeacetylaseApplication 62445022Pending
- Bicyclic Inhibitors Of Histone DeacetylaseApplication PCTUS2016040956Pending
- Hetero-halo Inhibitors Of Histone DeacetylaseApplication PCTUS2016040957Pending
- Bicyclic Inhibitors Of Histone DeacetylaseApplication 62188854Pending
- Monocyclic Inhibitors Of Histone DeacetylaseApplication 62188857Pending
- Inhibitors Of Histone DeacetylaseApplication PCTUS2015037667Pending
- Inhibitors Of Histone DeacetylaseApplication 62017688Pending
- Synthesis Of Bicyclic Inhibitors Of Histone DeacetylaseApplication 62877363Pending
- Bicyclic Inhibitors Of Histone DeacetylaseApplication PCTUS2018045528Pending
- Bicyclic Inhibitors Of Histone DeacetylaseApplication PCTUS2018013262Pending
- Bicyclic Inhibitors Of Histone DeacetylaseApplication PCTUS2018013260Pending
- Bicyclic Inhibitors Of Histone DeacetylaseApplication 62555298Pending
- Bicyclic Inhibitors Of Histone DeacetylaseApplication 62541807Pending
Related companies, and why
- ACHIEVE LIFE SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- CELLIBRE INCSimilar federal contract value in Biotech · null in contracts
- ALIDA BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- OSSIUM HEALTH INCSimilar federal contract value in Biotech · null in contracts
- NUSIRT SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- CERSCI THERAPEUTICS INCORPORATEDSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .